The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility ...

0:53 - VGK goal called back: A would-be Ivan Barbashev goal is wiped out after a review showed Vegas was guilty of offsides on the score 1:54 - VGK goal: Knights bounce right back from the non ...

FINAL— Blues beat VGK 5-4 in a shootout. The Golden Knights didn't have their best on their last road trip as they lost each of the three games. Vegas will keep that trip in the rearview mirror ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial ...

CAMBRIDGE, Mass., February 14, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a ...